TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: SF-36 physical-component score improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SF-36 mental-component score improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Interobserver agreement percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraobserver agreement percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disagreements in classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot eversion during early stance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood oxygen level-dependent signal increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain during movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function (Disabilities of the Arm, Shoulder, and Hand assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful outcome defined by fragments smaller than 4 mm or stone-free status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implicit and explicit memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean maximal walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative mortality
Endpoint domain: Mortality/survival
Primary endpoint: Fluid infusion volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endoscopic field of view
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood loss per minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mild, dry brassy cough incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Hypotension incidence
Endpoint domain: Adverse events/effects
Primary endpoint: in-stent neo-intimal hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: angiographic in-segment restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulmonary static compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Alveolar-arterial oxygen difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anemia prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Objective RECIST response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevention of Acute Mountain Sickness (AMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to return to normal diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood to recommend surgery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum FGF23 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PTTR (Prothrombin Time in Therapeutic Range)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first therapeutic INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maintenance dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of antioxidant enzymes (CAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of antioxidant enzymes (SOD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of antioxidant enzymes (GPX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite cardiovascular endpoint
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of fibrosing colonopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: pain relief after laparoscopic surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local anesthetic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: net clinical outcome (death, myocardial infarction, urgent target-vessel revascularization, major bleeding)
Endpoint domain: Mortality/survival
Primary endpoint: PAI‐1 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebral Blood Flow (CBF) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-rater agreement for bronchovascular markings and/or reticular densities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inter-rater agreement for nodular densities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inter-rater agreement for parenchymal consolidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Accuracy of lung sliding diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of lung sliding diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance of disease management tasks
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: health‐related self‐efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: patient‐initiated communications
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: risk of new cardiac events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: children's general language development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean visual score for beam‐hardening artifacts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global strain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Segmental strain prediction of recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month MHQ score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Development of alveolar osteitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: venous access time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: reduction in procedural pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in absolute pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in creatinine concentration > or = 25% 48 hours after the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Decrease in p53 immunostaining density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: pain score at 120 min postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of clinical pregnancy
Endpoint domain: Physiological/clinical
Primary endpoint: Live birth
Endpoint domain: Physiological/clinical
Primary endpoint: subjective heat pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective heat pain unpleasantness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavior rating using the Frankl scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cell proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caspase-3 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opportunistic Diseases (ODs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Normalization of hemodynamic responses to L-arginine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: hospitalized VCD episodes
Endpoint domain: Mortality/survival
Primary endpoint: Effective rate of manipulative reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort degree of manipulation reduction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement score of DHI
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adherence to capecitabine therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Histological incorporation of grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pain and discomfort scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of additional drops required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mucosal bleeding time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of nonmuscle invasive bladder cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Resistance to retrieval damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of side branch wiring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of eyes with conjunctival bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Inflammation of the anterior chamber
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ovoid separation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical function (SF‐36‐PFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ischaemia-driven target lesion revascularization (ID-TLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Definite stent thrombosis (ST)
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events related to EVL
Endpoint domain: Adverse events/effects
Primary endpoint: hand-eye coordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of good or excellent intubating conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Procollagen type III N-terminal amino peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: eGFR decrease rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: HBsAg/Ab seroconversion by 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HBsAg clearance by 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HBeAg/Ab seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the number of anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diarrheal episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: total number of days ill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean days ill per person per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in daily activities and quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: skin infections
Endpoint domain: Adverse events/effects
Primary endpoint: sick days
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: light-duty days
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: prevention of fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: serum NET levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum estradiol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: risk of ovulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: postprandial serum parathyroid hormone suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Dissemination in space (DIS) classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with CPG relating to ACE inhibitor dose on discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Compliance with CPGs relating to increasing ACE inhibitors doses
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Compliance with the contents of the discharge letter
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Objective response rate (CR + PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reocclusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Aesthetic improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Subject satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Glycosylated hemoglobin A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin resistance (HOMA Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC(0-24) h of serum progesterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-24) h of saliva progesterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-24) h of capillary blood progesterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: advanced AMD development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CNV development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: GA development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fasting serum glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in delayed recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvement in executive functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Low Birth Weight (LBW) infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total cost related to CHF
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 1-mm vertical bone fill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: >50% vertical bone fill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-mm vertical defect fill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate-specific antigen testing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of prostate cancer screening
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Immunoglobulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cutaneous reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total nasal symptom medication score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle fibre size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of tuberculosis (TB)
Endpoint domain: Mortality/survival
Primary endpoint: Significant hepatitis requiring discontinuation of INH
Endpoint domain: Adverse events/effects
Primary endpoint: locoregional relapse rate
Endpoint domain: Mortality/survival
Primary endpoint: improved survival
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dating violence perpetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRQL dimensions
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: suppression of energy intake by protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in muscle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eyelash growth or darkening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Three-year overall survival rate
Endpoint domain: Mortality/survival
Primary endpoint: freedom from angiographic cardiac allograft vasculopathy
Endpoint domain: Mortality/survival
Primary endpoint: Migraine recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excess episodes of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantities of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in symptoms of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cognitive and behavioural change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvements in areas of life including self-care, work and relationships
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: MLHFQ scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Circulating ALT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac function grading and LVEF improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Atrial tachyarrhythmia recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sinus rhythm without antiarrhythmic drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: skin laxity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: fat reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intra-operative thermal burns
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in insulin sensitivity (ISGD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection pain measured by VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: DAS28-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAQ-DI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: total cholesterol/HDL-C ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 8-week mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients experiencing complete resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of episodes recorded during the study period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on FMA‐UE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on WMFT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on MAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validity of plain-radiography with dose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apathy improvement
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: objective clinical progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of residual stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Salivary CgA concentration levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Mood Disturbance (TMD) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Performance on arithmetic task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: biomarkers of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: parameters related to the metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: symptom-free status after 24 months of treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Posterior vitreous penetration ratio (PVPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes